either PFS (P ¼ 0.63) or OS (P ¼ 0.52), nor did IgV H mutational status. However, patients with mutated IgV H had a longer treatment-free survival compared with those with unmutated IgV H (Figure 3) .
Negative prognostic impact of PTEN mutation in pediatric T-cell acute lymphoblastic leukemia We have recently shown that constitutive activation of PI3K/Akt signaling pathway is a very common event in pediatric T-cell acute lymphoblastic leukemia (T-ALL) and is critical for leukemic cell viability. PI3K/Akt pathway hyperactivation appears to result mainly from post-translational inactivation of the phosphatase and tensin homolog (PTEN) protein, which is the main negative regulator of PI3K/Akt pathway. 1 However, a Letters to the Editor relatively small but significant subset of newly diagnosed T-ALL patient samples are known to present inactivating PTEN gene mutations. [1] [2] [3] [4] [5] PTEN mutation may collaborate with PTEN post-translational inactivation to maximize PTEN functional deficiency, thus contributing to increased PI3K/Akt activation and finally to leukemia resistance to chemotherapy. In fact, the occurrence of PTEN mutation/deletion is highly frequent in human T-ALL cell lines derived from relapsed patients. Moreover, PTEN mutation was reported to occur in 2 of 35 relapsed T-ALL as a secondary event during disease progression. 3 As discussed below, the clinical relevance of PTEN mutations in pediatric T-ALL is available for only a limited number of patients 4, 6 and should be analyzed with caution. Here, we report the prognostic impact of PTEN exon 7 mutations in a larger series of consecutive pediatric ALL patients treated in a single institution. Our results favor the notion that PTEN mutations can have a prognostic impact in pediatric T-ALL.
Bone marrow samples were obtained at diagnosis from 63 and 71 consecutive children (41 month and o18, except for a 19-and 23-year-old T-ALL patients) with previously untreated T-ALL and precursor B-cell ALL, respectively. The group of T-ALL patients had a partial overlap with those we previously reported in the context of the post-translational inactivation of PTEN protein (18/63). 1 Patients were registered at Boldrini Children's Center between 2000 and 2008, and were treated according to the Brazilian GBTLI ALL-99 Childhood Treatment protocol. 7 Three T-ALL patients received corticosteroid before diagnosis but all had 450% blasts in diagnostic bone marrow aspirates and accordingly were included in the study. One patient had no DNA available (final n ¼ 62). Median follow-up was 4.4 years (interquartile range 2.4-6.8 years) for patients still alive and 1.4 years for those who died (interquartile range 0.3-1.8 years). The study was approved by the Research Ethics Committee from both Centro Infantil Boldrini and State University of Campinas.
Several independent studies have previously shown that PTEN mutations in primary T-ALL occur almost exclusively in exon 7. [1] [2] [3] [4] In this study, we screened for mutations in exon 7 and also exon 1, because we previously identified one patient harboring a mutation in that exon in conjunction with exon 7 mutation. 1 The PTEN exon 1 and 7 coding and flanking intronic sequences were amplified by PCR 1 and polymorphisms were screened by a method based on homo-heteroduplex formation. To validate the homo-heteroduplex methodology, all 62 PCR products of exon 7 from T-ALL samples were sequenced. We found PTEN exon 7 mutations in 11 out of 62 T-ALL (17.7%, CI: 8.2-27.2%), but in none of 71 precursor B-cell ALL patients. All T-ALL samples harboring PTEN mutations by direct DNA sequencing analysis were correctly classified by the simplified homo-heteroduplex technique. Even single nucleotide differences were also detected by the homo/heteroduplex analysis. We did not find any additional T-ALL patients presenting exon 1 mutations.
Although there is evidence for constitutive activation of PI3K/Akt pathway in precursor B-cell ALL our results suggest that PTEN mutations (at least affecting exon 1 and 7) are absent or rare in the most common type of childhood ALL. In contrast, they represent a relatively frequent genetic abnormality in childhood T-ALL, occurring in approximately 18% of the cases. Other studies found PTEN-inactivating mutations in 5% (2/38), 2 8% (9/111), 3 and 27% (12/44) 4 of T-ALL samples. The limited number of samples analyzed and/or different methodologies may explain these discrepancies. Also, our PCR methodology did not allow for the detection of putative allele/exon deletions (except homozygous deletions), which were recently found to occur in 4% (2/47 4 and 3/72 5 ) of T-ALL samples. Recently, Larson Gedman et al. 6 sequenced cDNA samples and found far higher frequency of PTEN mutations (63%, 27/43) that, in contrast to previous studies, [2] [3] [4] extended to most PTEN exons. However, many of the proposed cDNA mutations correspond to the sequence of the PTEN pseudogene, which is known to be transcribed. Therefore, the prevalence and range of PTEN gene alterations may have been overestimated.
PTEN mutations clustered in a narrow region of exon 7 and resulted in predicted C-terminal PTEN protein truncations in all but one of the cases. Although these mutations preserve the phosphatase domain of the protein, PTEN proteins lacking their C-terminal domain are reported to be rapidly degraded. Patients belonging to the Low-Risk classification of GBTLI ALL-99, 7 thus excluded from survival analysis of Figure 1 .
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Of the 11 patients with PTEN mutations, two had homozygous PTEN mutations, one had both alleles affected by distinct exon 7 mutations and one had both exon 1 and 7 mutations (Table 1) . 1 PTEN protein expression was abrogated or strikingly reduced (data not shown) in these four patients, herein classified as having biallelic PTEN abnormalities. In addition, one T-ALL patient had a t(3;10)(p21;q23-26) chromosomal rearrangement (data not shown). PTEN gene is known to be located on chromosome 10q23.3. For this patient, all exons were sequenced, but no evidence of DNA mutations was found. Notwithstanding, PTEN protein was absent in western blot assays (data not shown) and so this patient was considered to have PTEN abnormalities in both alleles, resulting in a 'silenced' gene, functionally similar to those four harboring biallelic PTEN abnormalities.
As shown in Table 1 , all but one of the patients harboring PTEN alterations were CALLA negative (P ¼ 0.044). Importantly, four out of the five patients (80%) harboring biallelic PTEN abnormalities failed to reach remission at the end of the induction therapy, in contrast to only 8 in 57 (14%) with the wild type or with monoallelic mutations (P ¼ 0.004; Fisher's test). In addition, all of them had 4100 000/ml WBC at diagnosis, contrary to only 28 of 57 (49%) of the patients in the other two groups (P ¼ 0.055; Fisher's test). No other association could be found between PTEN status and other clinical and biological variables at diagnosis (Table 2 ).
Survival analysis indicated that patients harboring any PTEN gene alteration (n ¼ 12) had a tendency toward inferior overall survival (OS 48.6 ± 14.8 versus 69.4 ± 7.4%, P ¼ 0.07) and eventfree survival (EFS 48.6±14.8 versus 65.2±7.7%, P ¼ 0.15) than those without this genetic lesion. Patients with a 'silenced' PTEN gene (n ¼ 5) had the lowest estimated probability of surviving (40 ± 21.9%), whereas patients with no detected abnormality (n ¼ 50) had the highest (69.4±7.4%), and those harboring monoallelic mutations (n ¼ 7) displayed an intermediate value (53.6±20.1%; P ¼ 0.04, log-rank test for trend; Figure 1a) .
The majority of patients (n ¼ 55) was classified in the high-risk group and was treated more intensively than those in the lowrisk group (n ¼ 7). When separate analysis for the high-risk group was undertaken, PTEN mutations were significantly associated with lower OS (37.5 ± 16.1 versus 67.9 ± 8.1%; P ¼ 0.019; Figure 1b ) and EFS (37.5 ± 16.1 versus 63.1 ± 8.5%; P ¼ 0.052).
Our results contradict very recent findings by Larson Gedman et al. 6 , which reported that PTEN mutations had no prognostic significance in pediatric T-ALL. 6 However, these authors may have overestimated (B3-fold) the number of patients with PTEN None of these clinical variables affected patients' survival, except for the presence of more than 5% blasts in BM of day 28, and absence of hematological remission, which were associated with lower overall survival (both Po0.001). mutations by having sequenced the PTEN pseudogene. Gutierrez et al. 4 reported that genetic alterations in the PTEN-PI3K-AKT pathway, including PTEN truncating mutations (n ¼ 12), did not predict event-free survival. In contrast, the same authors reported that PTEN deletions, as determined by FISH analysis, were significantly associated with early treatment failure in three out of four patients and may contribute to increased resistance to induction chemotherapy. This observation is compatible with our findings regarding patients harboring biallelic PTEN abnormalities. The apparent discrepancies between these studies regarding the prognostic impact of exon 7 PTEN mutations may be attributed to the small number of patients analyzed or to differences in the treatment protocols. Besides, PTEN post-translational inactivation, which is very frequent in primary T-ALL but does not occur in all patients to the same degree, 1 might act as a confounding factor in the different studies, which focus strictly on PTEN gene lesions. Importantly, our current observations suggest that T-ALL patients harboring exon 7 PTEN mutations may be at increased risk of relapse.
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